Drugs / ANG-3070
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05387785 | Jun → Nov 2022 | idiopathic pulmonary fibrosis | Angion Biomedica Corp | Unknown | No outcome recorded |
| Phase 1 | NCT04196179 | Dec 2019 → Nov 2020 | — | Angion Biomedica Corp | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04939116 | Dec 2021 → Jul 2023 | glomerular disorder, proteinuria | Angion Biomedica Corp | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANG3070 | “ANG-3070 in Healthy Adult Participants” NCT04196179 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor” NCT04939116 ↗ |
| Route | Oral | “A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral” NCT04196179 ↗ |